Voyager Therapeutics Inc. (VYGR): Technicals Say You should Hold

Voyager Therapeutics Inc. (NASDAQ:VYGR) saw an upside of 44.53% to close Friday at $5.55 after adding $1.71 on the day. The 5-day average trading volume is 56,246,363 shares of the company’s common stock. It has gained $5.73 in the past week. An average of 14,186,471 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,818,364.

VYGR’s 1-month performance is 67.67% or $2.22 on its low of $2.46 reached on 10/05/21. The company’s shares have touched a 52-week low of $2.46 and high of $12.65, with the stock’s rally to the 52-week high happening on 01/15/21. YTD, VYGR has lost -22.38% or -$1.60. However, the current price is down -56.13%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On May 21, 143 days have gone by since the last insider trading activity for Voyager Therapeutics Inc. (VYGR). Khwaja Omar (See remarks) most recently sold 3,516 shares at $4.03 per share on May 21. This transaction cost the insider $14,169. President & CEO, Turenne Andre, sold 7,977 shares at a price of $7.55 on Feb 11. Then, on Feb 11, Chief Financial Officer Dorval Allison sold 3,186 shares at a price of $7.55 per share. This transaction amounted to $24,054.

Valuation Metrics

The company’s PE ratio for the last five years has touched a high of 12.07 and a low of 3.825. VYGR stock has a beta of 1.08. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.10 while the price-to-book (PB) in the most recent quarter is 1.89.

Voyager Therapeutics Inc.’s quick ratio for the period ended June 29 was 6.00, with the current ratio over the same period at 6.00 meaning that VYGR stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is 18.23% while for the period ending June 29; Voyager Therapeutics Inc.’s operating margin was 5.00%. The firm’s gross profit as reported stood at $143.74 million against revenue of $171.13 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Voyager Therapeutics Inc.’s cash and short-term investments amounted to $25.14 million against total debt of $45.72 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected VYGR to announce -$0.71 per share in earnings in its latest quarter, but it posted -$0.8, representing a -12.70% surprise. EBITDA for the quarter stood at more than -$27.29 million. VYGR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 98.19 million, with total debt at $45.72 million. Shareholders hold equity totaling $37.94 million

Technical Picture

Let’s look briefly at Voyager Therapeutics Inc. (VYGR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 87.51% to suggest the stock is trending Overbought, with historical volatility in this time period at 283.84%.

The stock’s 5-day moving average is $3.66, reflecting a +112.64% or $2.94 change from its current price. VYGR is currently trading +68.18% above its 20-day SMA, +20.92% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +73.98% and -38.54% respectively.

Stochastic %K and %D was 87.52% and 58.30% and the average true range (ATR) pointed at 0.51. The RSI (14) points at 82.26%, while the 14-day stochastic is at 94.50% with the period’s ATR at 0.40. The stock’s 9-day MACD Oscillator is pointing at 1.18 and 1.28 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Voyager Therapeutics Inc. (NASDAQ: VYGR), Robert W. Baird upgraded it to an Outperform rating. They previously had a Neutral rating on the stock. Analysts offering their rating for VYGR stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate VYGR as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 3 have offered a “buy” rating.

What is VYGR’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $3.00 and a high of $14.00, with their median price target at $5.25. Looking at these predictions, the average price target given by analysts is for Voyager Therapeutics Inc. (VYGR) stock is $6.69.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam